Ensemble Therapeutics Corp.

Ensemble Discovery is pioneering the development of a novel category of drugs called Ensemblins, which are small molecule macrocyclic compounds that can mimic the effects of biologics and interfere with protein-protein interactions. The company employs two distinctive platforms to facilitate the creation of these molecules. The first platform is their exclusive DNA-Programmed Chemistry (DPC), which allows for the rapid generation and screening of hundreds of thousands of Ensemblins. The second platform involves the synthesis of Ensemblins as individual molecules using traditional chemistry techniques.